Tirzepatide
Molecular Research Profile · Target purity > 99.0% · Half-life ~5 days
Dual GIP/GLP-1 receptor agonist with high efficacy in glycemic modulation and research-grade body composition optimization.
Mechanism of Action
Tirzepatide is a unimolecular dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. Unlike single-agonist GLp-1 peptides (e.g., semaglutide), tirzepatide engages both incretin pathways simultaneously, producing a synergistic effect on insulin secretion, gastric emptying, and satiety signaling.
The GIP component enhances insulin sensitivity in adipose tissue and promotes lipid buffering, while the GLP-1 component reduces food intake via hypothalamic and hindbrain circuits. This dual mechanism yields greater glycemic control and body-weight reduction than GLP-1 monotherapy at equivalent doses. The ~5-day half-life (engineered via a C20 fatty diacid chain) supports once-weekly research protocols.
Tirzepatide's balanced GIP/GLP-1 potency ratio differentiates it from earlier GIP/GLP-1 co-agonists that were biased toward GIP and showed limited metabolic benefit. The optimized ratio was key to its clinical efficacy.
Research History & Context
Tirzepatide (LY3298176, brand name Mounjaro in clinical contexts) was developed by Eli Lilly. Phase 3 SURPASS and SURMOUNT trials (2021–2024) demonstrated mean body-weight reductions of up to 22.5% at 72 weeks in participants with obesity, and HbA1c reductions of up to 2.4% in type-2 diabetes populations. It received clinical authorization in 2022 for type-2 diabetes and expanded indications in 2023.
As a research peptide, tirzepatide is among the most extensively characterized GLP-1-family compounds available through independent analytical laboratories, with robust HPLC/MS reference data and well-documented reconstitution protocols.
Storage & Handling
Store lyophilized tirzepatide powder at -20°C, protected from light and moisture. Under these conditions, stability exceeds 18 months. Brief excursions to room temperature during handling (<24 hours) do not significantly degrade the peptide.
Reconstituted tirzepatide in bacteriostatic water should be refrigerated at 2–8°C and used within 28 days. Avoid agitation — tirzepatide solutions are more sensitive to aggregation from shaking than some other GLP-1 peptides. If cloudiness or visible particles develop, discard the vial.
Reconstitution & Research Dosing
For Tirzepatide, the standard laboratory reconstitution is 2.0 ml BAC water for 15mg vial. A typical research study window uses 2.5 mg - 7.5 mg / week.
For a 15mg research vial, add 2.0 ml BAC water to achieve 7.5 mg/ml. For lower-concentration protocols (e.g., 2.5 mg/ml for micro-dosing studies), use 6.0 ml BAC water for the same 15mg vial. Always confirm the net peptide weight via third-party HPLC before dosing calculations.
Use the Reconstitution Calculator for exact syringe units →Explore Related Research Compounds
Research Use Only (RUO): Tirzepatide is discussed strictly as an in-vitro laboratory research compound. Nothing on this page constitutes human or clinical administration guidance. Always verify purity through independent third-party HPLC/MS analysis before use.